Etrumadenant
ARC-2 (AB928CSP0002)
Phase 1 small_molecule completed
Quick answer
Etrumadenant for TNBC - Triple-Negative Breast Cancer is a Phase 1 program (small_molecule) at Arcus Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Arcus Biosciences
- Indication
- TNBC - Triple-Negative Breast Cancer
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed